Advertisement
Advertisement

Top 25 Most-Viewed Articles on The Body PRO

CROI 2017 Preview: New Research on HIV Cure and Treatment
Don't Get Left Behind: New Scientific Findings to Be Presented at CROI 2017
Research Shows 47% Reduction in STIs Among Gay Men Who Took Doxycycline After Sex
No Evidence of Accelerated Brain Aging in HIV-Positive People on Effective ART
Final HIV Research Highlights From CROI 2017
What to Expect for CROI 2017
Targeting Latently Infected Cells via IFITM1
Eliciting Accurate Responses About Substance Use
Large Study Finds Mental Health Issues Common Among HIV-Positive People
Multidrug-Resistant HIV Transmission Despite Adherence to PrEP
Research Update: Meta-Analysis Shows PrEP Is Effective in Women With High Adherence
Research Update: Youth Who Use Drugs Who Cannot Access Addiction Treatment Are Twice as Likely to Start Injecting
Early Reports From CROI 2017
This Week in HIV Research: Diabetes Rate Higher Among People With HIV; and 8-Week Hepatitis C Treatment for HIV/HCV Coinfection
Depression, Anxiety Tied to Imperfect Adherence in Gay Men With Newly Diagnosed HIV
Antibodies Could Offer a More 'Natural' and Safer HIV Treatment or Prevention Option
HIV Transmission Despite Adherence to PrEP and No Drug Resistance
New HIV Infections Drop 18% in 6 Years
Bictegravir versus Dolutegravir: Phase 2 Results of New Integrase Inhibitor
In the Eye of the Storm: One Doctor's 30-Year Journey Through the AIDS Crisis
NRTI GS-9131 Resurfaces at CROI 2017: In Vitro Sensitivity to Nuke-Resistant HIV
This Week in HIV Research: Kidney Function Improves With Protease Inhibitor Switch; and Viral Load Blips Predict Post-Treatment Control
Two-Drug Regimen Shines in HIV Treatment Switch Study
Diabetes Rate 3.8% Higher in People Living With HIV in National U.S. Comparison
NIH Research Helps Explain How Antibody Treatment Led to Sustained Remission of HIV-Like Virus




This article was provided by TheBodyPRO.com.
 

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.